Formulation and Pharmacokinetics of Thermosensitive Stealth® Liposomes Encapsulating 5-Fluorouracil

[1] Lammers T(2012)Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress J Control Release 161 175-187

[2] Kiessling F(2012)Macromolecular therapeutics in cancer treatment: the EPR effect and beyond J Control Release 164 138-144

[3] Hennink WE(2005)Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma J Steroid Biochem Mol Biol 94 111-121

[4] Storm G(2013)Towards more effective advanced drug delivery systems Int J Pharm 454 496-511

[5] Maeda H(2001)Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature Cancer Res 61 3027-3032

[6] Maillard S(2005)Lysolipid incorporation in dipalmitoylphosphatidylcholine bilayer membranes enhances the ion permeability and drug release rates at the membrane phase transition Biochim Biophys Acta Biomembr 1716 77-96

[7] Ameller T(2013)Materials characterization of the low temperature sensitive liposome (LTSL): effects of the lipid composition (lysolipid and DSPE-PEG2000) on the thermal transition and release of doxorubicin Faraday Discuss 161 515-534

[8] Gauduchon J(1978)Design of liposomes for enhanced local release of drugs by hyperthermia Science 202 1290-1293

[9] Gougelet A(2006)Should continuous infusion 5-fluorouracil become the standard of care in the USA as it is in Europe? Cancer Investig 24 50-55

[10] Gouilleux F(2010)A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy Cancer Chemother Pharmacol 65 979-988

[1] Lammers T(2012)Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress J Control Release 161 175-187

[2] Kiessling F(2012)Macromolecular therapeutics in cancer treatment: the EPR effect and beyond J Control Release 164 138-144

[3] Hennink WE(2005)Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma J Steroid Biochem Mol Biol 94 111-121

[4] Storm G(2013)Towards more effective advanced drug delivery systems Int J Pharm 454 496-511

[5] Maeda H(2001)Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature Cancer Res 61 3027-3032

[6] Maillard S(2005)Lysolipid incorporation in dipalmitoylphosphatidylcholine bilayer membranes enhances the ion permeability and drug release rates at the membrane phase transition Biochim Biophys Acta Biomembr 1716 77-96

[7] Ameller T(2013)Materials characterization of the low temperature sensitive liposome (LTSL): effects of the lipid composition (lysolipid and DSPE-PEG2000) on the thermal transition and release of doxorubicin Faraday Discuss 161 515-534

[8] Gauduchon J(1978)Design of liposomes for enhanced local release of drugs by hyperthermia Science 202 1290-1293

[9] Gougelet A(2006)Should continuous infusion 5-fluorouracil become the standard of care in the USA as it is in Europe? Cancer Investig 24 50-55

[10] Gouilleux F(2010)A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy Cancer Chemother Pharmacol 65 979-988